| Defining the risk of SARS-CoV-2 variants on immune protection MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ... Nature 605 (7911), 640-652, 2022 | 160 | 2022 |
| Mapping SARS-CoV-2 antigenic relationships and serological responses SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ... Science 382 (6666), eadj0070, 2023 | 103 | 2023 |
| BA. 2 and BA. 5 omicron differ immunologically from both BA. 1 omicron and pre-omicron variants A Rössler, A Netzl, L Knabl, H Schäfer, SH Wilks, D Bante, ... Nature communications 13 (1), 7701, 2022 | 70 | 2022 |
| SARS-CoV-2 variant vaccine boosters trial: preliminary analyses AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ... MedRxiv, 2022 | 36 | 2022 |
| Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ... Nature medicine 29 (9), 2334-2346, 2023 | 34 | 2023 |
| Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography A Rössler, A Netzl, L Knabl, D Bante, SH Wilks, W Borena, D Von Laer, ... Nature Communications 14 (1), 5224, 2023 | 29 | 2023 |
| Analysis of SARS-CoV-2 omicron neutralization data up to 2021-12-22 A Netzl, S Tureli, E LeGresley, B Mühlemann, SH Wilks, DJ Smith BioRxiv, 2021.12. 31.474032, 2022 | 26 | 2022 |
| Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382: eadj0070 SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ... | 11 | 2023 |
| Immunogenicity of the BA. 1 and BA. 4/BA. 5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial AR Branche, NG Rouphael, C Losada, LR Baden, EJ Anderson, ... Clinical Infectious Diseases 77 (4), 560-564, 2023 | 9 | 2023 |
| Mapping SARS-CoV-2 antigenic relationships and serological responses. bioRxiv (2022) SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ... preprint, 0 | 7 | |
| Immunogenicity of the BA. 1 and BA. 4/BA. 5 SARS-CoV-2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial AR Branche, NG Rouphael, C Losada, LR Baden, EJ Anderson, ... medRxiv, 2023 | 6 | 2023 |
| Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography. Nat Commun 14: 5224 A Rössler, A Netzl, L Knabl, D Bante, SH Wilks, W Borena, D von Laer, ... | 6 | 2023 |
| Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera A Rössler, A Netzl, L Knabl, SH Wilks, B Mühlemann, S Türeli, A Mykytyn, ... npj Vaccines 9 (1), 85, 2024 | 5 | 2024 |
| Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays B Mühlemann, SH Wilks, L Baracco, M Bekliz, JM Carreño, VM Corman, ... Science translational medicine 16 (747), eadl1722, 2024 | 5 | 2024 |
| Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant immunologic landscape (COVAIL) trial A Branche, N Rouphael, D Diemert, A Falsey, C Losada, LR Baden, ... Research Square, rs. 3. rs-2653179, 2023 | 4 | 2023 |
| Diminished secretion and function of IL-29 is associated with impaired IFN-α response of neonatal plasmacytoid dendritic cells L Wisgrill, I Wessely, A Netzl, L Pummer, K Sadeghi, A Spittler, A Berger, ... Journal of Leukocyte Biology 106 (5), 1177-1185, 2019 | 4 | 2019 |
| Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA. 1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial NG Rouphael, AR Branche, DJ Diemert, AR Falsey, C Losada, LR Baden, ... The Journal of infectious diseases 228 (12), 1662-1666, 2023 | 2 | 2023 |
| Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera B Mühlemann, SH Wilks, L Baracco, M Bekliz, JM Carreño, VM Corman, ... bioRxiv, 2023 | 2 | 2023 |
| Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost B Zhang, Y Fong, L Dang, J Fintzi, S Chen, J Wang, NG Rouphael, ... Nature Communications 16 (1), 759, 2025 | 1 | 2025 |
| Nonhuman primate antigenic cartography of SARS-CoV-2 A Rössler, A Netzl, N Lasrado, J Chaudhari, B Mühlemann, SH Wilks, ... Cell Reports 44 (1), 2025 | | 2025 |
